CN110177773B - 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 - Google Patents
苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 Download PDFInfo
- Publication number
- CN110177773B CN110177773B CN201880006856.6A CN201880006856A CN110177773B CN 110177773 B CN110177773 B CN 110177773B CN 201880006856 A CN201880006856 A CN 201880006856A CN 110177773 B CN110177773 B CN 110177773B
- Authority
- CN
- China
- Prior art keywords
- group
- pharmaceutically acceptable
- alkyl
- compound
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17153384.7 | 2017-01-26 | ||
| EP17153384 | 2017-01-26 | ||
| PCT/EP2018/051384 WO2018138027A1 (en) | 2017-01-26 | 2018-01-22 | Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceuticalcompositions and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN110177773A CN110177773A (zh) | 2019-08-27 |
| CN110177773B true CN110177773B (zh) | 2023-08-25 |
Family
ID=57906576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201880006856.6A Active CN110177773B (zh) | 2017-01-26 | 2018-01-22 | 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10919859B2 (https=) |
| EP (1) | EP3573952B1 (https=) |
| JP (1) | JP7023969B2 (https=) |
| CN (1) | CN110177773B (https=) |
| WO (1) | WO2018138027A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3573959B1 (en) * | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| US10913720B2 (en) * | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7050792B2 (ja) * | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| CN110214135B (zh) * | 2017-01-26 | 2023-02-21 | 勃林格殷格翰国际有限公司 | 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途 |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| TWI707849B (zh) | 2018-02-13 | 2020-10-21 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| IL295825A (en) | 2020-02-28 | 2022-10-01 | Kallyope Inc | gpr40 agonists |
| WO2021236617A1 (en) | 2020-05-19 | 2021-11-25 | Kallyope, Inc. | Ampk activators |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| WO2023192170A1 (en) * | 2022-04-01 | 2023-10-05 | Merck Sharp & Dohme Llc | Process for preparing ((1s,2s)-2-(5-methylpyridin-2-yl)cyclopropyl)methanol |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004041266A1 (ja) * | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| WO2005051890A1 (en) * | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| EP1916234A1 (en) * | 2005-07-29 | 2008-04-30 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| EP2096109A1 (en) * | 2006-12-01 | 2009-09-02 | Astellas Pharma Inc. | Carboxylic acid derivative |
| WO2009157418A1 (ja) * | 2008-06-25 | 2009-12-30 | 第一三共株式会社 | カルボン酸化合物 |
| WO2013178575A1 (en) * | 2012-05-30 | 2013-12-05 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarb oxylic acids |
| CN104684907A (zh) * | 2012-08-02 | 2015-06-03 | 默沙东公司 | 抗糖尿病的三环化合物 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US628476A (en) | 1898-03-18 | 1899-07-11 | Joseph Howard Kirk | Junction of cycle, motor-car, or other frames, &c. |
| US2505322A (en) | 1945-09-14 | 1950-04-25 | Gibson Refrigerator Co | Refrigerator cabinet |
| US2560111A (en) | 1946-11-07 | 1951-07-10 | Raymond T Levine | Buffing chuck |
| US2656003A (en) | 1948-02-27 | 1953-10-20 | Inst Of Inventive Res | High explosive disk-shaped charge for seismic exploration |
| US2727340A (en) | 1953-08-31 | 1955-12-20 | Alfred S Zanotta | Portable tool for reconditioning crane rails |
| US5356287A (en) | 1987-03-16 | 1994-10-18 | Mcintyre Kevin M | Simulating presence |
| US7135575B2 (en) | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1630152A4 (en) | 2003-05-30 | 2009-09-23 | Takeda Pharmaceutical | CONDENSED CYCLIC COMPOUND |
| US7786165B2 (en) | 2004-03-15 | 2010-08-31 | Takeda Pharmaceutical Company Limited | Aminophenylpropanoic acid derivative |
| DE102004017930A1 (de) | 2004-04-14 | 2005-11-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel |
| JP2008530162A (ja) | 2005-02-15 | 2008-08-07 | グラクソ グループ リミテッド | グルタミン酸受容体を増強する化合物および医薬におけるそれらの使用 |
| WO2006103503A1 (en) | 2005-03-28 | 2006-10-05 | Pfizer Japan Inc. | Substituted aryloxoethyl cyclopropanecarboxamide compounds as vr1 receptor antagonists |
| US7664629B2 (en) | 2005-07-19 | 2010-02-16 | Xerox Corporation | Second language writing advisor |
| JP2009530237A (ja) | 2006-03-15 | 2009-08-27 | ノイロサーチ アクティーゼルスカブ | キナゾリノン及びカリウムチャネル活性化剤としてのその使用 |
| EP2006271A4 (en) | 2006-03-30 | 2011-08-10 | Asahi Kasei Pharma Corp | SUBSTITUTED BICYCLIC CYCLIC DERIVATIVE AND USE THEREOF |
| BRPI0713378A8 (pt) | 2006-06-27 | 2018-01-02 | Takeda Pharmaceutical | composto, pró-droga, modulador da função do receptor gpr40, agente farmacêutico uso do composto, e, método de produção de uma forma opticamente ativa de um composto |
| JP2011016722A (ja) | 2007-10-23 | 2011-01-27 | Astellas Pharma Inc | チアゾリジンジオン化合物 |
| ES2345916B1 (es) | 2008-10-14 | 2011-09-14 | Clipdorfix, S.L. | Dispositivo de fijacion liberable de elementos adosados. |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| WO2010051819A1 (en) | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
| WO2010143733A1 (en) | 2009-06-09 | 2010-12-16 | Takeda Pharmaceutical Company Limited | Novel fused cyclic compound and use thereof |
| WO2011094890A1 (en) | 2010-02-02 | 2011-08-11 | Argusina Inc. | Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators |
| CA2799414A1 (en) | 2010-05-18 | 2011-11-24 | Merck Sharp & Dohme Corp. | Spiro isoxazoline compounds as sstr5 antagonists |
| TW201643169A (zh) | 2010-07-09 | 2016-12-16 | 艾伯維股份有限公司 | 作為s1p調節劑的螺-哌啶衍生物 |
| AR084050A1 (es) | 2010-12-01 | 2013-04-17 | Boehringer Ingelheim Int | Acidos indaniloxidihidrobenzofuranilaceticos |
| WO2012111849A1 (en) | 2011-02-17 | 2012-08-23 | Takeda Pharmaceutical Company Limited | Production method of optically active dihydrobenzofuran derivative |
| US8642585B2 (en) | 2012-03-26 | 2014-02-04 | Boehringer Ingelheim International Gmbh | Indanyloxydihydrobenzofuranylacetic acids |
| WO2014019186A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| PE20150968A1 (es) | 2012-11-28 | 2015-07-09 | Boehringer Ingelheim Int | Nuevos acidos indaniloxi dihidrobenzofuranil aceticos |
| JP6283862B2 (ja) | 2012-12-07 | 2018-02-28 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規インダニルオキシジヒドロベンゾフラニル酢酸 |
| EP2963027B1 (en) | 2013-02-28 | 2018-12-26 | TiumBio Co., Ltd. | Tricyclic compound and use thereof |
| CN105473595A (zh) | 2013-08-23 | 2016-04-06 | 福建海西新药创制有限公司 | 治疗糖尿病的羧酸化合物 |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| CN110088089B (zh) * | 2016-10-25 | 2023-08-29 | 勃林格殷格翰国际有限公司 | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 |
| US10913720B2 (en) | 2017-01-26 | 2021-02-09 | Boehringer Ingelheim International Gmbh | Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| EP3573959B1 (en) * | 2017-01-26 | 2021-07-28 | Boehringer Ingelheim International GmbH | Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof |
| JP7050792B2 (ja) | 2017-01-26 | 2022-04-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 |
| US10550127B1 (en) | 2017-02-08 | 2020-02-04 | Boehringer Ingelheim International Gmbh | Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes |
-
2018
- 2018-01-22 CN CN201880006856.6A patent/CN110177773B/zh active Active
- 2018-01-22 EP EP18703220.6A patent/EP3573952B1/en active Active
- 2018-01-22 WO PCT/EP2018/051384 patent/WO2018138027A1/en not_active Ceased
- 2018-01-22 JP JP2019540094A patent/JP7023969B2/ja active Active
- 2018-01-22 US US16/479,224 patent/US10919859B2/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004041266A1 (ja) * | 2002-11-08 | 2004-05-21 | Takeda Pharmaceutical Company Limited | 受容体機能調節剤 |
| WO2005051890A1 (en) * | 2003-11-19 | 2005-06-09 | Smithkline Beecham Corporation | Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40 |
| EP1916234A1 (en) * | 2005-07-29 | 2008-04-30 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| WO2007033002A1 (en) * | 2005-09-14 | 2007-03-22 | Amgen Inc. | Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders |
| EP2096109A1 (en) * | 2006-12-01 | 2009-09-02 | Astellas Pharma Inc. | Carboxylic acid derivative |
| WO2009157418A1 (ja) * | 2008-06-25 | 2009-12-30 | 第一三共株式会社 | カルボン酸化合物 |
| WO2013178575A1 (en) * | 2012-05-30 | 2013-12-05 | Boehringer Ingelheim International Gmbh | New indanyloxyphenylcyclopropanecarb oxylic acids |
| CN104684907A (zh) * | 2012-08-02 | 2015-06-03 | 默沙东公司 | 抗糖尿病的三环化合物 |
Non-Patent Citations (1)
| Title |
|---|
| 王杰 等.基于GPR40受体新药的研制进展.药物生物技术.2016,第23卷(第1期),第86-90页. * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3573952B1 (en) | 2021-07-14 |
| WO2018138027A1 (en) | 2018-08-02 |
| EP3573952A1 (en) | 2019-12-04 |
| CN110177773A (zh) | 2019-08-27 |
| US20190352266A1 (en) | 2019-11-21 |
| JP7023969B2 (ja) | 2022-02-22 |
| US10919859B2 (en) | 2021-02-16 |
| JP2020505400A (ja) | 2020-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110177773B (zh) | 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途 | |
| JP7049349B2 (ja) | ベンジルアミノピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| CN110198928B (zh) | 苄氧基吡啶基环丙烷甲酸、其药物组合物和用途 | |
| CN110088089B (zh) | 苄基氨基吡啶基环丙烷甲酸、药物组合物及其用途 | |
| JP7050792B2 (ja) | ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用 | |
| JP7049353B2 (ja) | 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物 | |
| JP6816107B2 (ja) | インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用 | |
| CN110312706B (zh) | 茚满基氨基吡啶基环丙烷甲酸、其药物组合物及用途 | |
| JP5913752B2 (ja) | 新規インダニルオキシジヒドロベンゾフラニル酢酸 | |
| CN110214135B (zh) | 茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途 | |
| JP2018526405A (ja) | ［｛［２，３−ジヒドロ−１Ｈ−インデン−１−イル］アミノ｝−２Ｈ，３Ｈ−フロ［３，２−ｂ］ピリジン−３−イル］酢酸、それらの医薬組成物および使用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TG01 | Patent term adjustment | ||
| TG01 | Patent term adjustment |